NextCure Presented Phase 1b Study Results of NC410 with Pembrolizumab at ESMO 2024

BELTSVILLE, MD, USA I September 16, 2024 I NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company dedicated to developing unique cancer therapies, has revealed clinical data from the Phase 1b part of their Phase 1b/2 study on NC410, a LAIR-2 fusion protein, in partnership with pembrolizumab. This ongoing trial is targeting ovarian cancer and microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) that are either immune checkpoint inhibitor (ICI) naïve or refractory. The presented data show promising clinical activity in these difficult-to-treat cancers.

The study findings were recently shared at ESMO 2024 by Emese Zsiros, M.D., Ph.D., Associate Professor of Oncology and Chair of the Department of Gynecologic Oncology at Roswell Park Comprehensive Cancer Center for the ovarian cancer segment. Eric S. Christenson, M.D., Assistant Professor of Oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, presented the colorectal cancer segment. The full presentations can be accessed on the NextCure website.

Udayan Guha, M.D., Ph.D., NextCure’s Senior Vice President of Clinical and Translational Development, commented on the study results, emphasizing the continued clinical activity observed with the NC410 and pembrolizumab combination against ovarian cancer and MSS/MSI-L CRC. These cancers typically do not respond well to immunotherapy. Guha highlighted that patients showing clinical benefits, such as partial responses or stable disease, experienced meaningful and durable responses. The ongoing follow-up of patients still enrolled in the study is expected to provide further updates later this year.

The presentation details are as follows:

1. Title: Results of the Phase 1b Study of NC410 Combined with Pembrolizumab in Ovarian Cancer Patients
Lead Author: Emese Zsiros, M.D., Ph.D.
Presentation Number: 758P

2. Title: Results of the Phase 1b Study of NC410 Combined with Pembrolizumab in MSS/MSI-L Colorectal Cancer Patients
Lead Author: Eric S. Christenson, M.D.
Presentation Number: 577P

NextCure, Inc. is a clinical-stage biopharmaceutical company with a mission to advance new medicines aimed at treating cancer patients who do not respond to or have disease progression on current therapies. The company's approach involves leveraging their strength in understanding biological pathways and biomarkers, cell interactions within the tumor microenvironment, and the impact of these interactions on biological responses. Their focus includes developing antibody-drug conjugates, antibodies, and proteins with differentiated mechanisms of action to provide new therapeutic options for cancer patients.

For more information and to view the presentations, visit the NextCure website.